Prime Medicine appoints Allan Reine as CFO, effective Jan 17, 2024

Prime Medicine, Inc.

Allan Reine named CFO and principal financial officer; previously CFO of Foghorn Therapeutics.
Receives $500k base salary, $176k sign-on bonus, 40% target annual bonus, and option grants (600k time-vesting shares + 250k milestone-based shares).
Carman Alenson transitions from interim CFO to SVP Finance and CAO; remains principal accounting officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Allan Reine

Chief Financial Officer

PRME · Prime Medicine, Inc.

Effective: 2024-01-17
Filed: January 5, 2024, 6:59 PM ET

On January 4, 2024, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Reine was appointed as Chief Financial Officer at Prime Medicine, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 4, 2024, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.

View on SEC.gov

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-000524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.